

# Active substances set

**Search phrase:** tisagenlecleucel

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

## non-Hodgkin lymphoma

| | | |
|---|---|---|
| **Tisagenlecleucel** | Tisagenlecleucel is indicated for the treatment of: - Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. - Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. | REIMBURSEMENT WITH RESTRICTIONS<br>ESMO |

## Acute lymphoid leukemia

| | | |
|---|---|---|
| **Tisagenlecleucel** | Tisagenlecleucel is indicated for the treatment of paediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse. | FULL REIMBURSEMENT<br>ESMO |